Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

NCT06549465 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

PSMA PET-Positive Castration-Resistant Prostate Cancer

Interventions

BIOLOGICAL: In-111 rosopatamab tetraxetan
BIOLOGICAL: 45 kBq/kg Ac-225 rosopatamab tetraxetan
BIOLOGICAL: 55 kBq/kg Ac-225 rosopatamab tetraxetan
BIOLOGICAL: 60 kBq/kg Ac-225 rosopatamab tetraxetan

Sponsor

Convergent Therapeutics